

# 1 **Ensitrelvir Fumaric Acid in Patients with SARS-CoV-2:**

## 2 **A Retrospective Chart Review**

3 **Masaya Yamato,<sup>1</sup> Masahiro Kinoshita,<sup>2</sup> Shogo Miyazawa,<sup>3</sup> Masayuki Seki,<sup>1</sup> Tomoki Mizuno,<sup>1</sup>**

4 **Takuhiro Sonoyama<sup>4</sup>**

5

### 6 **Affiliations:**

7 <sup>1</sup>Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center,  
8 Izumisano, Japan

9 <sup>2</sup>Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan

10 <sup>3</sup>Data Science Department, Shionogi & Co., Ltd., Osaka, Japan

11 <sup>4</sup>Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan

12

13 **Correspondence:** Takuhiro Sonoyama

14 Vice President, Medical Science Department, Shionogi & Co., Ltd.

15 3-1-8, Doshomachi, Chuo-ku, Osaka 541-0045, Japan

16 e-mail: [takuhiro.sonoyama@shionogi.co.jp](mailto:takuhiro.sonoyama@shionogi.co.jp)

17 **Alternate corresponding author:** Masahiro Kinoshita

18 Global Medical Affairs Lead, Medical Affairs, Shionogi & Co., Ltd.

19 3-1-8, Doshomachi, Chuo-ku, Osaka 541-0045, Japan

20 e-mail: [masahiro.kinoshita@shionogi.co.jp](mailto:masahiro.kinoshita@shionogi.co.jp)

21

22 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

23 **Word Count:** 3261

24 **Tables/Figures:** 3/1

25 **Supplementary Tables/Figures:** 1/0

26

27 **ABSTRACT**

28 **Introduction:** Antivirals with differing mechanisms of action are needed for COVID-19 treatment;  
29 remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting.  
30 Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022,  
31 based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its  
32 efficacy in hospitalized patients is lacking.

33 **Case presentations:** This case series reports outcomes for all patients who received ensitrelvir whilst  
34 hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022–  
35 April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg).  
36 Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various  
37 underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%).  
38 Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were  
39 antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with  
40 rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure.  
41 Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the  
42 investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in  
43 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals  
44 were observed.

45 **Discussion:** This case series represents ensitrelvir clinical efficacy in hospitalized patients with SARS-  
46 CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-  
47 treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite  
48 this, no patients experienced progression of COVID-19 to severe or critical disease, including those  
49 who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here  
50 indicates it is a viable treatment option for SARS-CoV-2 infection in this setting.

51 **Conclusion:** Ensitrelvir was associated with potent antiviral activity and positive clinical outcomes in  
52 high-risk, hospitalized patients with various comorbidities.

53 **Trial Registration:** UMIN000051300

54

55 **Keywords:** SARS-CoV-2; Ensitrelvir; COVID-19; Viral load; Viral persistence; Remdesivir-failure

56

### 57 **Key Summary Points**

58 *Why carry out this study?*

- 59 • Real-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings,  
60 is required.
- 61 • This was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a  
62 range of disease severities and comorbidities, including patients who had experienced remdesivir  
63 treatment failure.

64 *What was learned from the study?*

- 65 • All patients experienced clinical improvement following ensitrelvir treatment, without any  
66 worsening COVID-19.
- 67 • Viral clearance was documented in 78.1% of patients at final viral measurement.
- 68 • No new safety signals of ensitrelvir were observed in this analysis.

69

70 **INTRODUCTION**

71 The first cases of the novel coronavirus disease (COVID-19) caused by severe acute respiratory  
72 syndrome coronavirus 2 (SARS-CoV-2) infection were identified in Wuhan City, Hubei Province, China,  
73 in December 2019[1]. Following the global spread of infections, the World Health Organization  
74 (WHO) declared COVID-19 a pandemic in March 2020[2]. As of June 2023, there have been  
75 ~768,000,000 confirmed cases and ~6,900,000 deaths reported to the WHO[3], including  
76 ~33,800,000 cases and ~75,000 deaths reported in Japan[3]. Since its identification as a variant of  
77 concern (VOC) in November 2021, the Omicron variant and its sublineages have been the dominant  
78 SARS-CoV-2 variants worldwide, responsible for the vast majority of reported cases[4-6]. Compared  
79 with previous VOC's (particularly Delta), the Omicron variant is associated with reduced symptom  
80 severity[7-10], but increased transmission[11-13] and immune evasion[14, 15]. Whilst Omicron  
81 infection generally leads to less severe outcomes than Delta, its increased transmissibility led to a  
82 significant healthcare burden globally; Japan's sixth, seventh, and eighth COVID-19 waves, caused by  
83 Omicron infection, were associated with the highest levels of COVID-19 cases and deaths reported  
84 since the start of the pandemic[3].

85 Booster vaccines and hybrid immunity (immunity developed from both vaccination and previous  
86 SARS-CoV-2 infection) consistently provide high protection against Omicron-related severe disease,  
87 but their effectiveness wanes over time[16-18]; furthermore, many monoclonal antibodies  
88 previously used to treat people infected with SARS-CoV-2 have demonstrated reduced neutralization  
89 and binding affinity to the Omicron variant and its sublineages[19, 20]. Patients with severe  
90 comorbidities are still at increased risk of poor outcomes when infected with the Omicron variant,  
91 including progression to severe disease and death[21-23]. Additionally, patients with severe  
92 comorbidity burden and immunocompromised patients, including those on hemodialysis[24], are  
93 likely to be at more risk from prolonged viral shedding and viral persistence[25-29]. This can increase  
94 the overall disease burden for these patients, for example by interfering with the management of  
95 underlying diseases in patients with hematological malignancies[30, 31]. An antiviral agent that can

96 rapidly reduce SARS-CoV-2 virus levels and prevent viral persistence would therefore be a beneficial  
97 treatment option for this patient population.

98 Remdesivir is an intravenously administered antiviral, which is indicated in Japan for the treatment of  
99 COVID-19 in patients: with oxygen saturation  $\leq 94\%$ ; who require supplementary oxygen; or with  
100 pneumonia because of SARS-CoV-2[32]. Nirmatrelvir/ritonavir (Paxlovid<sup>®</sup>) and molnupiravir  
101 (Lagevrio<sup>®</sup>) are oral antivirals for the treatment of COVID-19; both have received emergency  
102 authorization in many countries, including Japan, for the treatment of patients infected with SARS-  
103 CoV-2, with risk factors for severe disease. Nirmatrelvir/ritonavir also received the United States  
104 Food and Drug Administration's full approval in May 2023[33]. In clinical trials in non-hospitalized  
105 patients, both drugs demonstrated significantly lower rates of hospitalization or death versus  
106 placebo[34, 35], and reductions in SARS-CoV-2 viral ribose nucleic acid by day 5[34, 36]. However,  
107 approval for both drugs was based on clinical trials in unvaccinated individuals, before Omicron  
108 became the predominant SARS-CoV-2 strain[34, 35]. Since then, nirmatrelvir/ritonavir failed to meet  
109 the primary endpoint of self-reported, sustained alleviation of all symptoms in non-hospitalized  
110 patients at low risk of progressing to severe disease in the phase 2/3 EPIC-SR study[37].

111 Ensitrelvir fumaric acid (Xocova<sup>®</sup>) is an oral antiviral, developed by Shionogi & Co., Ltd. for the  
112 treatment of infection caused by SARS-CoV-2. Ensitrelvir acts through the same mechanism as  
113 nirmatrelvir, inhibiting the 3C-like protease, which is essential for viral replication and processing of  
114 the polyprotein encoded by the SARS-CoV-2 gene[38]. In the recently reported phase 3 trial  
115 SCORPIO-SR, ensitrelvir met the primary endpoint and demonstrated a significantly shorter time to  
116 resolution of five symptoms typical of Omicron infection compared with placebo ( $-24.3$  hours; 95%  
117 CI  $- 78.7$  to  $11.7$ ;  $p = 0.04$ ) in patients aged 12–69 with mild-to-moderate COVID-19[39]. Based on  
118 these data, as well as efficacy from the phase 2b part[40], ensitrelvir received emergency  
119 authorization in Japan for the treatment of SARS-CoV-2 infection. In addition, ensitrelvir has  
120 demonstrated rapid and significant reductions in SARS-CoV-2 viral RNA: a 30-fold reduction in mean

121 viral RNA levels compared with placebo at day 4 [mean difference  $-1.47 \log_{10}$  tissue culture  
122 infectious dose (TCID<sub>50</sub>)/mL] was recorded in the SCORPIO-SR trial[39]. Ensitrelvir treatment in  
123 hospitalized patients is being investigated in the ongoing STRIVE study[41].

124 Despite positive outcomes reported in clinical trials, evidence on the efficacy and safety of ensitrelvir  
125 in clinical practice is limited. The aim of this retrospective chart review was to evaluate the treatment  
126 status, including patient background and treatment outcomes, of patients treated with ensitrelvir in  
127 Japan, November 2022 and April 2023, immediately after emergency approval of ensitrelvir in  
128 November 2022 and when the Omicron variant was dominant.

129

130 **METHODS**

131 **Study Design/Period**

132 This was a single center, retrospective chart review of patients prescribed ensitrelvir for the  
133 treatment of SARS-CoV-2 infection, from November 2022 to April 2023 in the Rinku General Medical  
134 Center. Ensitrelvir (375/125 mg) was dosed orally once a day for five days, where 375 mg was dosed  
135 on day 0 as a loading dose and 125 mg was dosed on days 1–4 as a maintenance dose.

136 **Patient Population**

137 All patients who received ensitrelvir between November 2022 and April 2023 were included in the  
138 study. Only patients for whom the following data were obtained were included in the analytical  
139 population (Fig. 1): start and end date of ensitrelvir treatment; a SARS-CoV-2 positive test result;  
140 SARS-CoV-2 virus test results [antigen test, reverse transcription polymerase chain reaction (RT-PCR)]  
141 after starting administration of ensitrelvir; clinical outcomes of SARS-CoV-2 infection. Patients were  
142 excluded from the analytical population if they were not treated in accordance with ensitrelvir  
143 prescribing instruction or if they refused to participate in the study. This current paper reports results  
144 for hospitalized patients only.

145 **Data Collection**

146 Data were collected using electronic medical records of the Rinku General Medical Center.  
147 Pseudonymized information was aggregated and analyzed as anonymized information using an  
148 anonymization tool (CoNaxs®, Conax Automomation Sdn. Bhd).

149 The study collected general information of patients including gender, age, date of COVID-19 onset,  
150 underlying disease/complications, pre-treatment and post-treatment for SARS-CoV-2 infection,  
151 concomitant medications, previous SARS-CoV-2 infection history, and SARS-CoV-2 vaccination status  
152 (number of vaccinations and time of last vaccination).



153 Treatment information collected included ensitrelvir administration start and end date, prior  
154 therapies, and concomitant drug use.

155 Clinical information was also collected, including imaging findings, body temperature (axillary),  
156 clinical signs and symptoms, level of consciousness, and oxygen saturation. Disease severity at the  
157 start of ensitrelvir administration was classified by investigator according to the Japanese guideline  
158 on COVID-19 treatment (Supplementary Table 1)[42]. The presence/absence of pneumonia, oxygen  
159 administration (including flow rate), mechanical ventilation, and intensive care unit (ICU)  
160 management were also recorded, as well as the implementation status of dialysis. Finally, clinical  
161 outcomes of SARS-CoV-2 infection and any adverse events (AEs) related to ensitrelvir were recorded.

162 Virological information collected consisted of SARS-CoV-2 virus test results (antigen test, RT-PCR).  
163 Quantitative antigen level in nasopharyngeal swab was assessed using Lumipulse<sup>®</sup> (Fujirevio, Tokyo,  
164 Japan), with a maximum viral antigen level of 5,000 pg/mL and a cut-off value of 1.34 pg/mL. It has  
165 previously been reported that a cut-off value of 89.73 pg/mL corresponds to a cycle threshold (Ct)  
166 value of  $\geq 35$  by quantitative PCR[43]. When estimating the infectivity of SARS-CoV-2, a Ct value  $\geq 35$   
167 is often used as a marker for non-infectious viral levels[44-46]. Therefore, we defined viral clearance  
168 as an antigen level of  $< 89.73$  pg/mL. Viral rebound was defined as an increase of antigen level of  $\geq$   
169 89.73 pg/mL after viral clearance.

## 170 **Endpoints**

171 The primary endpoint of the study was viral antigen or PCR results (quantitative or qualitative  
172 results) at each time point from the start of administration to 10 days after the end of ensitrelvir  
173 administration. The secondary endpoint was investigator-assessed improvement at the end of  
174 ensitrelvir treatment (day 4 following administration of ensitrelvir). Exploratory endpoints included  
175 presence or absence of hospitalization; ICU admission; and death up to 14 days after the start of

176 administration. Safety of ensitrelvir treatment was also assessed, by recording any treatment-related  
177 AEs. No statistical analyses were performed as this was a descriptive study.

178

## 179 **RESULTS**

### 180 *Patient disposition and baseline characteristics*

181 Fifty-two patients with SARS-CoV-2 infection who received ensitrelvir were identified between  
182 November 2022 and April 2023 at Rinku General Medical Center. One was excluded due to co-usage  
183 of contraindicated drugs. In total, 32 of the included patients were hospitalized and 19 were  
184 outpatients (Fig. 1). Here we report the outcomes for the 32 hospitalized patients only, all of whom  
185 completed 5 days of ensitrelvir treatment. Outcomes for the 19 outpatients will be reported in detail  
186 separately, due to the limited follow-up data available.

187 Within the hospitalized analytical population ( $N = 32$ ), the average age was 73.5 years old, and 25  
188 (78.1%) patients were age 65 years and older (Table 1). At the start of ensitrelvir treatment, 21/32  
189 (65.6%) patients had mild COVID-19 disease severity; four (12.5%) had moderate I severity; and  
190 seven (21.9%) had moderate II severity (Table 1), according to the Japanese guideline. All seven  
191 patients with moderate II disease were on inhaled oxygen therapy and eight patients (25%) had  
192 evidence of pneumonia at the start of ensitrelvir treatment (two with moderate I disease and six  
193 with moderate II) (Table 1). Prior antiviral therapy had been administered to 29/32 (90.6%) patients,  
194 including all 11 patients with moderate I or II disease (Table 1). The most common prior therapy was  
195 remdesivir [27/32 (84.4%)], either delivered as monotherapy [ $n = 24$  (75%)] or alongside  
196 casirivimab/imdevimab [ $n = 3$  (9.4%)], and 21/27 (77.8%) patients received  $\geq 3$  days of remdesivir  
197 (mean 6.6 days, range 3–22 days). One patient (3.1%) received casirivimab/imdevimab monotherapy  
198 and one patient (3.1%) received molnupiravir monotherapy. Patients were switched to ensitrelvir

199 based on investigator assessments of clinical and virological status: either clinical symptoms were not  
200 resolved, or viral clearance was required for further medical procedures.

201 A higher proportion of patients with moderate I or II disease [2/4 (50.0%) and 4/7 (57.1%),  
202 respectively] were unvaccinated for SARS-CoV-2, compared with patients with mild disease [5/21  
203 (23.8%)] (Table 1). The most common concomitant medications were antihypertensives [19 (59.4%)]  
204 and corticosteroids [10 (31.2%)]. One (3.1%) patient received immunosuppressants (cyclosporine),  
205 and 18 (58.1%) received precautioned medicines (medicines included in the “Precautions for  
206 concomitant use” section of the prescribing instructions due to potential interactions with  
207 ensitrelvir). Two (6.3%) patients received rituximab in the days before ensitrelvir treatment (days –49  
208 and –16, respectively). Seven (22.6%) patients received hemodialysis. Patients exhibited a wide range  
209 of underlying diseases: the most common underlying comorbidity was hypertension [25/32 (78.1%)]  
210 followed by chronic kidney disease [8/32 (25.0%)], cerebral infarction [7/32 (21.9%)], diabetes  
211 mellites [7/32 (21.9%)], and dyslipidemia [7 (21.9%)]. Ten patients (31.3%) had malignant tumor.  
212 Individual patient demographics and characteristics can be seen in Table 2.

### 213 *Virology outcomes*

214 All 32 patients received the full five days of ensitrelvir treatment (days 0–4) (Table 3). Viral clearance  
215 (antigen level < 89.73 pg/mL ) was observed by day 5 in 18/32 (56.3%) patients and antigen level  
216 below lower the limit of quantification (cut-off level: < 1.34 pg/mL) was observed in 5/32 (15.6%)  
217 patients by day 5. Viral clearance was observed at final measurement in 25/32 (78.1%) patients and a  
218 final antigen quantification measurement of < 1.34 pg/mL was observed in 20/32 (62.5%) patients.  
219 Viral rebound after end of ensitrelvir treatment was observed in four (12.5%) patients: two (Patient 9  
220 and Patient 14) had neither rebound of clinical symptoms, nor additional antiviral treatment; one  
221 (Patient 25) had no rebound of clinical symptoms but received remdesivir from day 8 to day 13; and  
222 one (Patient 28) experienced transient increase of body temperature  $\geq 37.5$  degree Celsius at the  
223 time of viral rebound and received remdesivir treatment from day 11 to day 15, with viral clearance

224 observed on day 14 and day 15. No disease progression was observed in these four cases. In a  
225 subgroup analysis of 21 patients who switched to ensitrelvir following failure of  $\geq 3$  days remdesivir  
226 treatment or remdesivir plus casirivimab/imdevimab, 13/21 (61.9%) achieved viral clearance by day  
227 5. Patient 18 did not achieve viral clearance and received remdesivir between day 7 and day 11, as  
228 well as meropenem for aspirational pneumonia with onset after completion of ensitrelvir treatment.

### 229 *Secondary clinical outcomes and exploratory endpoints*

230  
231 All 32 patients achieved clinical improvement as assessed by the investigator at the end of ensitrelvir  
232 therapy (day 4 following administration of ensitrelvir). Six (18.8%) patients (Patient 2, 4, 17, 18, 27  
233 and 28) experienced a transient increase of body temperature to  $\geq 37.5$  degree Celsius after end of  
234 ensitrelvir treatment. No patients were admitted to the ICU and no patients died up to 14 days  
235 following administration of ensitrelvir. In addition, no patients progressed to severe disease over the  
236 course of the study. Sixteen patients were discharged from hospital before day 14, and fifteen were  
237 discharged after day 14 (range: day 14–77). One patient (Patient 24) died on day 59; this death was  
238 considered unrelated to COVID-19 and due to an underlying comorbidity of ANCA-associated  
239 vasculitis.

### 240 *Safety*

241 No ensitrelvir treatment-related AEs were observed, and ensitrelvir treatment was not discontinued  
242 for any patient.

243

## 244 **DISCUSSION**

245 Here we report the first case series for hospitalized patients treated with ensitrelvir for SARS-CoV-2  
246 infection following emergency approval in November 2022. Whilst ensitrelvir has demonstrated rapid  
247 alleviation of symptoms in its clinical studies[39, 40, 47], the efficacy of ensitrelvir in patients  
248 hospitalized with COVID-19 is unclear. Also, the current Japanese guideline on COVID-19 treatment

249 recommends ensitrelvir for the treatment of mild/moderate I disease only, regardless of the  
250 presence of any risk factors for severe disease[42]. This case series represents clinical efficacy of  
251 ensitrelvir treatment in hospitalized patients with SARS-CoV-2 in a real-world setting, and has  
252 demonstrated successful ensitrelvir use in this population, including patients with moderate II  
253 disease severity. This study included a high-risk patient population who had severe comorbidities and  
254 an average age of 73.5 years. Despite this, all patients achieved clinical improvement as assessed by  
255 the investigator at day 4 and no cases of ICU admission or death occurred over 14 days, indicating  
256 that ensitrelvir successfully prevented progression to severe disease in this high-risk group.

257 In this case series, ensitrelvir also demonstrated antiviral activity; viral clearance (defined in the  
258 methods section) was achieved by day 5 in 18/32 (56.3%) patients. Viral persistence is an unmet  
259 need for patients with COVID-19, particularly for immunocompromised patients[25, 26] and patients  
260 with comorbidities[28, 29] for whom COVID-19 infection is associated with negative outcomes[21-23,  
261 48, 49]. Prolonged SARS-CoV-2 infection has been linked with rapid viral evolution[50, 51], and it has  
262 also been hypothesized that viral persistence may increase the likelihood of long COVID[52-54].  
263 Furthermore, reductions in viral titer and load following antiviral therapy have been linked to  
264 reduction in mortality rates and improved symptom resolution[34, 55, 56] and may decrease the  
265 potential for SARS-CoV-2 transmission[55]. Therefore, it is important to reduce the viral load of SARS-  
266 CoV-2, both in the short and long term.

267 Whilst ensitrelvir in hospitalized patients is being investigated in the ongoing STRIVE study[41], the  
268 results of this case series align with reported clinical trial data for ensitrelvir in non-hospitalized  
269 patients. In the randomized, placebo-controlled, phase 3 SCORPIO-SR study, reduction from baseline  
270 in SARS-CoV-2 viral RNA on day 4 was significantly greater with ensitrelvir compared with placebo  
271 (least-squares mean [ $\log_{10}$  TCID<sub>50</sub>/mL]: -2.48 versus -1.01,  $p < .001$ )[39]. Information on viral RNA  
272 reduction in hospitalized patients for other oral antivirals is limited, but a recent phase 3 study of  
273 nirmatrelvir/ritonavir in hospitalized adult patients with severe comorbidities reported no significant

274 difference in duration of SARS–CoV-2 RNA clearance compared with placebo[57]. Not all patients  
275 achieved viral clearance following ensitrelvir treatment in this case series, but all patients improved  
276 clinically as determined by the investigator at day 4.

277 Of note, most patients (27/32) in this case series were treated with ensitrelvir after failure of  
278 remdesivir treatment (remdesivir alone or remdesivir plus casirivimab/imdevimab). Of these  
279 patients, 21 switched to ensitrelvir following failure of  $\geq 3$  days remdesivir treatment. All patients in  
280 this subgroup achieved investigator-judged clinical improvement at day 4, suggesting ensitrelvir is  
281 effective even when received  $\geq 3$  days after onset of infection, an outcome that has not yet been  
282 demonstrated in clinical trials[58]. These findings may mean that ensitrelvir could provide clinical  
283 benefit to patients even when it is administered at a delayed phase of the disease with persistent  
284 viral infection.

285 Currently available treatments, remdesivir and nirmatrelvir are not recommended for patients with  
286 eGFR  $<30$  mL/min. In this case series, seven patients received hemodialysis alongside ensitrelvir  
287 treatment, all of whom clinically improved, with no adverse event. Of the seven who received  
288 hemodialysis, three reported viral clearance by day 5 and five were discharged from hospital by day  
289 14. This suggests that ensitrelvir may be a viable treatment option for these patients.

290 This retrospective chart review has several limitations. It was a single center study, with a relatively  
291 small patient population and, given the nature of the study, there was no control group. As such, it is  
292 difficult to draw conclusions on the comparative efficacy and safety of ensitrelvir from this study  
293 alone. Secondly, due to the retrospective nature of the study, the evaluation and timings for each  
294 outcome do not necessarily match between patients. Not all patients had an antigen quantitative  
295 measurement taken after end of ensitrelvir treatment, nor did patients receive them on the same  
296 days. Additionally, although these were hospitalized patients, and so represent those impacted  
297 heavily by infection, most patients had mild disease severity on commencement of ensitrelvir. There  
298 were less than 10 patients in each of the moderate I and moderate II disease groups, limiting the

299 conclusions we can draw from these populations. Finally, there were no pre-specified or standardized  
300 criteria for: patients switching to ensitrelvir from remdesivir; the evaluation of clinical outcomes  
301 following ensitrelvir treatment; or discharge from hospital following ensitrelvir treatment. All  
302 decisions were based on the clinical judgement of the investigator.

303 The main strength of this study is that it reflects real-world use of ensitrelvir and outcomes in  
304 patients with a wide range of comorbidities. The study was also conducted after emergency approval  
305 of ensitrelvir in November 2022, during the Omicron era, representing the efficacy of ensitrelvir  
306 against this persisting variant.

307 Whilst ensitrelvir demonstrated efficacy in the majority of patients, there were cases where  
308 ensitrelvir failed to achieve viral clearance and cases of viral rebound and/or transient increase of  
309 body temperature. Three patients received post-antiviral treatment (remdesivir). There are several  
310 reports about rebound of SARS-CoV-2 and symptoms with nirmatrelvir–ritonavir and molnupiravir in  
311 hospitalized patients with COVID-19 [59], as well as non-hospitalized patients[60]. In this case series,  
312 only one patient developed both viral rebound and a transient increase in body temperature, but did  
313 not develop any other symptoms at the time of viral rebound. Overall, in this case series, viral  
314 rebound was not correlated with transient increase of body temperature, and did not lead to serious  
315 clinical outcomes, which is consistent with previous reports with other SARS-CoV-2 antivirals [59, 61].  
316 Further investigation of antiviral and clinical efficacy of ensitrelvir in hospitalized patients is  
317 warranted.

318

## 319 **CONCLUSIONS**

320 Ensitrelvir showed potent antiviral activity and was associated with positive clinical outcomes in a  
321 generally high-risk, hospitalized, elderly patient population with mild–moderate COVID-19 infection,  
322 including in those with a variety of comorbidities. In the majority of cases, ensitrelvir demonstrated  
323 potent antiviral activity despite previous remdesivir treatment failure and clinical improvement was

324 reported in all patients. Of note, no patients progressed to severe or critical diseases of COVID-19 in  
325 this generally high-risk population. This case series adds to the growing clinical information  
326 supporting the efficacy and safety of ensitrelvir for the treatment of patients infected with SARS-CoV-  
327 2, including those hospitalized with a range of high-risk factors, even when treatment was delayed  
328 beyond 72 hours from disease onset.

329



330 **ACKNOWLEDGEMENTS**

331 The authors would like to thank the patients and their families. Rinku General Medical Center used  
332 SIMPRESEARCH<sup>®</sup> as a data tabulation tool, and we would like to thank the SIMPRESEARCH<sup>®</sup>  
333 developer, 4DIN Ltd. The authors would also like to thank Tsukasa Horiyama for their contribution to  
334 manuscript development.

335

336 **Funding.** The implementation of this research was funded by Shionogi & Co., Ltd., Osaka, Japan.  
337 Shionogi & Co., Ltd. Also took in charge all costs associated with the development and publication of  
338 this manuscript, including the journal's Rapid Service Fee.

339 ***Medical Writing and Editorial Assistance.***

340 Editorial assistance in the preparation of this manuscript, under the direction of the authors, was  
341 provided by Ian McAllister, BSc, of Ashfield MedComms, an Inizio Company, funded by Shionogi &  
342 Co., Ltd., and complied with Good Publication Practice (GPP) guidelines (DeTora LM, et al. Ann Intern  
343 Med 2022;175:1298–1304).

344 ***Author Contributions.*** Masaya Yamato was responsible for research planning, study conception and  
345 design, acquisition of data, quality assurance, interpretation of results, drafting the article, and  
346 revising the article critically for important intellectual content. Masayuki Seki and Tomoki Mizuno  
347 were responsible for acquisition of data, quality assurance, drafting the article, and revising the  
348 article critically for important intellectual content. Masahiro Kinoshita, Shogo Miyazawa and Tomoki  
349 Sonoyama were responsible for research planning, interpretation of results, drafting the article, and  
350 revising the article critically for important intellectual content. All authors gave final approval before  
351 submission.

352 ***Disclosures.*** Masaya Yamato has received lecture fees from, and serves as an advisor for, Shionogi &  
353 Co., Ltd.. Masahiro Kinoshita, Shogo Miyazawa and Takuhiro Sonoyama are employees of Shionogi &

354 Co., Ltd.. Masayuki Seki and Tomoki Mizuno have nothing to disclose. This study was supported by  
355 Shionogi & Co., Ltd. In the form of all costs associated with the development and publication of this  
356 manuscript.

357 **Compliance with Ethics Guidelines.** The study was conducted in accordance with the Declaration of  
358 Helsinki, and approved by the Rinku General Medical Center Clinical Research Ethics Committee (2-  
359 23 Rinku Oraikita, Izumisano City 598-0048; protocol ID: 2023FY-I-001; date of approval 18 May  
360 2023). Patient consent was acquired using an opt-out procedure and no data were included that  
361 would allow identification of individual patients. This study was registered in UMIN Clinical Trials  
362 Registry (study ID: UMIN000051300).

363 **Data Availability.** All associated data are published within the main body of the manuscript and  
364 supplementary materials.

365

## 366 References

- 367 1. Helmy YA, Fawzy M, Elswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A  
368 Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and  
369 Control. *J Clin Med*. 2020;9(4). <https://doi.org/10.3390/jcm9041225>.
- 370 2. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11  
371 March 2020. [https://www.who.int/director-general/speeches/detail/who-director-general-s-  
372 opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020). Accessed Aug 9 2023.
- 373 3. WHO. WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>. Accessed Aug 9,  
374 2023.
- 375 4. WHO. One year since the emergence of COVID-19 virus variant Omicron.  
376 [https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-  
377 omicron#:~:text=It%20was%206%20November%202021,of%20the%20COVID%2D19%20pa  
378 ndemic](https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron#:~:text=It%20was%206%20November%202021,of%20the%20COVID%2D19%20pandemic). Accessed Aug 9, 2023.
- 379 5. Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and  
380 future perspectives. *Signal Transduct Target Ther*. 2022;7(1):141.  
381 <https://doi.org/10.1038/s41392-022-00997-x>.
- 382 6. Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated  
383 SARS-CoV-2 Omicron variant. *J Med Virol*. 2022;94(6):2376–83.  
384 <https://doi.org/10.1002/jmv.27643>.
- 385 7. Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to Omicron: Disease Severity and Clinical Outcomes  
386 of Major SARS-CoV-2 Variants. *J Infect Dis*. 2023;227(3):344–52.  
387 <https://doi.org/10.1093/infdis/jiac411>.
- 388 8. Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2)  
389 SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United  
390 Kingdom. *Lancet Reg Health Eur*. 2023;25:100556.  
391 <https://doi.org/10.1016/j.lanepe.2022.100556>.
- 392 9. Petrone D, Mateo-Urdiales A, Sacco C, et al. Reduction of the risk of severe COVID-19 due to  
393 Omicron compared to Delta variant in Italy (November 2021 - February 2022). *Int J Infect Dis*.  
394 2023;129:135–41. <https://doi.org/10.1016/j.ijid.2023.01.027>.
- 395 10. Strasser ZH, Greifer N, Hadavand A, Murphy SN, Estiri H. Estimates of SARS-CoV-2 Omicron  
396 BA.2 Subvariant Severity in New England. *JAMA Netw Open*. 2022;5(10):e2238354.  
397 <https://doi.org/10.1001/jamanetworkopen.2022.38354>.
- 398 11. Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases with  
399 Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December  
400 2021. *Euro Surveill*. 2022;27(6). <https://doi.org/10.2807/1560-7917.Es.2022.27.6.2200042>.
- 401 12. Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrado T,  
402 Aginagalde-Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and  
403 Serial Interval of SARS-CoV-2 Omicron Variant, Spain. *Emerg Infect Dis*. 2022;28(6):1224–8.  
404 <https://doi.org/10.3201/eid2806.220158>.
- 405 13. Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household secondary attack rates  
406 of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-  
407 analysis. *JAMA Netw Open*. 2022(5):e229317.  
408 <https://doi.org/10.1001/jamanetworkopen.2022.9317>.
- 409 14. Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant  
410 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med*.  
411 2022;386(7):698–700. <https://doi.org/10.1056/NEJMc2119236>.
- 412 15. Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant  
413 with an altered cell entry pathway. *Nat Microbiol*. 2022;7(8):1161–79.  
414 <https://doi.org/10.1038/s41564-022-01143-7>.

- 415 16. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection  
416 and hybrid immunity against the omicron variant and severe disease: a systematic review  
417 and meta-regression. *Lancet Infect Dis.* 2023;23(5):556–67. [https://doi.org/10.1016/s1473-](https://doi.org/10.1016/s1473-3099(22)00801-5)  
418 [3099\(22\)00801-5](https://doi.org/10.1016/s1473-3099(22)00801-5).
- 419 17. Lin DY, Xu Y, Gu Y, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. *N*  
420 *Engl J Med.* 2023;388(8):764–6. <https://doi.org/10.1056/NEJMc2215471>.
- 421 18. Solante R, Alvarez-Moreno C, Burhan E, et al. Expert review of global real-world data on  
422 COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of  
423 the pandemic. *Expert Rev Vaccines.* 2023;22(1):1–16.  
424 <https://doi.org/10.1080/14760584.2023.2143347>.
- 425 19. Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1  
426 and XBB. *N Engl J Med.* 2023;388(1):89–91. <https://doi.org/10.1056/NEJMc2214302>.
- 427 20. McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron  
428 immune evasion and receptor engagement. *Science.* 2022;375(6583):864–8.  
429 <https://doi.org/10.1126/science.abn8652>.
- 430 21. Cheong HH, Sio FI, Chan CC, et al. Clinical characteristics of COVID-19 patients infected by the  
431 Omicron variants in Macao, China: A cross-sectional study. *Health Sci Rep.* 2023;6(7):e1361.  
432 <https://doi.org/10.1002/hsr2.1361>.
- 433 22. Khadela A, Soni S, Megha K, Bhagat S, Chavda VP. A Review on the Impact of the SARS-CoV-2  
434 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities. 2023;3(2):138–57.  
435 <https://doi.org/10.3390/biologics3020008>.
- 436 23. Manchanda V, Mitra S, Rafique I, et al. Is Omicron really mild? – Comparative analysis of  
437 comorbidities and disease outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) and  
438 Delta (B.1.617.2) variants. *Indian J Med Microbiol;* 2023;45:100391.  
439 <https://doi.org/10.1016/j.ijmmb.2023.100391>.
- 440 24. Alfano G, Morisi N, Ferri C, et al. Prolonged RT-PCR test positivity in hemodialysis patients  
441 with COVID-19. *Ren Replace Ther.* 2023;9(1):35. [https://doi.org/10.1186/s41100-023-00487-](https://doi.org/10.1186/s41100-023-00487-y)  
442 [y](https://doi.org/10.1186/s41100-023-00487-y).
- 443 25. Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised Patients with Protracted  
444 COVID-19: a Review of "Long Persisters". *Curr Transplant Rep.* 2022;9(4):209–18.  
445 <https://doi.org/10.1007/s40472-022-00385-y>.
- 446 26. D'Abramo A, Vita S, Nicastri E. The unmet need for COVID-19 treatment in  
447 immunocompromised patients. *BMC Infect Dis.* 2022;22(1):930.  
448 <https://doi.org/10.1186/s12879-022-07918-x>.
- 449 27. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human  
450 body and brain at autopsy. *Nature.* 2022;612(7941):758–63.  
451 <https://doi.org/10.1038/s41586-022-05542-y>.
- 452 28. Pei L, Chen Y, Zheng X, et al. Comorbidities prolonged viral shedding of patients infected with  
453 SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. *J*  
454 *Infect Public Health.* 2023;16(2):182–9. <https://doi.org/10.1016/j.jiph.2022.12.003>.
- 455 29. Wang M, Mi H, Li N, et al. Association between the overall burden of comorbidity and Ct  
456 values among the older patients with Omicron infection: Mediated by inflammation. *Front*  
457 *Immunol.* 2023;14:11145044. <https://doi.org/10.3389/fimmu.2023.1145044>.
- 458 30. Marangoni D, Antonello RM, Coppi M, et al. Combination regimen of nirmatrelvir/ritonavir  
459 and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a  
460 scoping review of the literature. *Int J Infect Dis.* 2023;133:53–6.  
461 <https://doi.org/10.1016/j.ijid.2023.04.412>.
- 462 31. Arcani R, Colle J, Cauchois R, et al. Clinical characteristics and outcomes of patients with  
463 haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an  
464 important issue. *Ann Hematol.* 2021;100(11):2799–803. [https://doi.org/10.1007/s00277-](https://doi.org/10.1007/s00277-021-04656-z)  
465 [021-04656-z](https://doi.org/10.1007/s00277-021-04656-z).

- 466 32. Tsuzuki S, Hayakawa K, Uemura Y, et al. Effectiveness of remdesivir in hospitalized nonsevere  
467 patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry  
468 Japan. *Int J Infect Dis.* 2022;118:119–25. <https://doi.org/10.1016/j.ijid.2022.02.039>.
- 469 33. Harris E. FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment. *Jama.*  
470 2023;329(24):2118. <https://doi.org/10.1001/jama.2023.9925>.
- 471 34. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,  
472 Nonhospitalized Adults with Covid-19. *N Engl J Med.* 2022;386(15):1397–408.  
473 <https://doi.org/10.1056/NEJMoa2118542>.
- 474 35. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of  
475 Covid-19 in Nonhospitalized Patients. *N Engl J Med.* 2022;386(6):509–20.  
476 <https://doi.org/10.1056/NEJMoa2116044>.
- 477 36. Fischer WA, 2nd, Eron JJ, Jr., Holman W, et al. A phase 2a clinical trial of molnupiravir in  
478 patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of  
479 infectious virus. *Sci Transl Med.* 2022;14(628):eabl7430.  
480 <https://doi.org/10.1126/scitranslmed.abl7430>.
- 481 37. Pfizer. Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug  
482 Application Submission to U.S. FDA. 2022. [https://www.pfizer.com/news/press-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results)  
483 [release/press-release-detail/pfizer-announces-additional-phase-23-study-results](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results). Accessed  
484 Aug 8, 2023.
- 485 38. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, Tolerability, and  
486 Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL  
487 Protease Inhibitor, in Healthy Adults. *Antimicrob Agents Chemother.* 2022;66(10):e0063222.  
488 <https://doi.org/10.1128/aac.00632-22>.
- 489 39. Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for  
490 Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. 2023.  
491 <https://doi.org/10.1101/2023.07.11.23292264>.
- 492 40. Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With  
493 Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-  
494 Controlled, Phase 2/3 Study. *Clin Infect Dis.* 2023;76(8):1403–11.  
495 <https://doi.org/10.1093/cid/ciac933>.
- 496 41. ClinicalTrials.gov. Strategies and Treatments for Respiratory Infections & Amp; Viral  
497 Emergencies (STRIVE): Shionogi Protease Inhibitor.  
498 [https://classic.clinicaltrials.gov/ct2/show/NCT05605093?id=NCT05605093&draw=2&rank=1](https://classic.clinicaltrials.gov/ct2/show/NCT05605093?id=NCT05605093&draw=2&rank=1&load=cart)  
499 [&load=cart](https://classic.clinicaltrials.gov/ct2/show/NCT05605093?id=NCT05605093&draw=2&rank=1&load=cart). Accessed Aug 7, 2023.
- 500 42. Ministry of Health LaW, Japan. New Coronavirus Infectious Disease (COVID-19) Medical  
501 Treatment Guide Version 9.0. Ministry of Health LaW. 2023  
502 <https://www.mhlw.go.jp/content/000936655.pdf>. Accessed Aug 7, 2023.
- 503 43. Kase F, Ota T, Ota H, et al. Negative confirmation and infectivity estimation by quantitative  
504 antigen test of COVID-19 (Japanese language). *Jpn J of Med Tech.* 2022;71(2):250–6,  
505 [https://www.jstage.jst.go.jp/article/jamt/71/2/71\\_21-85/](https://www.jstage.jst.go.jp/article/jamt/71/2/71_21-85/article/-char/en) [article/-char/en](https://www.jstage.jst.go.jp/article/jamt/71/2/71_21-85/article/-char/en).
- 506 44. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral Cultures for Coronavirus Disease 2019  
507 Infectivity Assessment: A Systematic Review. *Clin Infect Dis.* 2021;73(11):e3884–e99.  
508 <https://doi.org/10.1093/cid/ciaa1764>.
- 509 45. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with  
510 RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro*  
511 *Surveill.* 2020;25(32). <https://doi.org/10.2807/1560-7917.Es.2020.25.32.2001483>.
- 512 46. Zhuang X, Zheng Y, Wei S, et al. Can the nucleic acid Ct value of discharged patients infected  
513 with SARS-CoV-2 Omicron variant be 35?--A retrospective study on fluctuation of nucleic acid  
514 Ct values in SNIEC mobile cabin hospital. *Front Cell Infect Microbiol.* 2022;12:1059880.  
515 <https://doi.org/10.3389/fcimb.2022.1059880>.


- 516 47. Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a  
517 Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-  
518 Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.  
519 Antimicrob Agents Chemother. 2022;66(10):e0069722. [https://doi.org/10.1128/aac.00697-  
520 22](https://doi.org/10.1128/aac.00697-22).
- 521 48. Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in  
522 immunocompromised patients: A nationwide study in Korea. PLoS One.  
523 2021;16(10):e0257641. <https://doi.org/10.1371/journal.pone.0257641>.
- 524 49. Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in  
525 immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid  
526 organ transplant patients. J Infect. 2021;82(3):329–38.  
527 <https://doi.org/10.1016/j.jinf.2021.01.022>.
- 528 50. Hettle D, Hutchings S, Muir P, Moran E. Persistent SARS-CoV-2 infection in  
529 immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study  
530 and literature review. Clin Infect Pract. 2022;16:100210.  
531 <https://doi.org/10.1016/j.clinpr.2022.100210>.
- 532 51. Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic  
533 infection. Nature. 2021;592(7853):277–82. <https://doi.org/10.1038/s41586-021-03291-y>.
- 534 52. Buonsenso D, Piazza M, Boner AL, Bellanti JA. Long COVID: A proposed hypothesis-driven  
535 model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc.  
536 2022;43(3):187–93. <https://doi.org/10.2500/aap.2022.43.220018>.
- 537 53. Chen B, Julg B, Mohandas S, Bradfute SB. Viral persistence, reactivation, and mechanisms of  
538 long COVID. Elife. 2023;12:e86015. <https://doi.org/10.7554/eLife.86015>.
- 539 54. Yang C, Zhao H, Espín E, Tebbutt SJ. Association of SARS-CoV-2 infection and persistence with  
540 long COVID. Lancet Respir Med. 2023;11(6):504–6. [https://doi.org/10.1016/s2213-  
541 2600\(23\)00142-x](https://doi.org/10.1016/s2213-2600(23)00142-x).
- 542 55. Huang C, Lu TL, Lin L. Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild  
543 to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A  
544 Meta-Analysis. Antibiotics (Basel). 2023;12(2). <https://doi.org/10.3390/antibiotics12020393>.
- 545 56. Lee E, Park S, Choi JP, et al. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against  
546 the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding. J Korean Med Sci.  
547 2023;38(8):e59. <https://doi.org/10.3346/jkms.2023.38.e59>.
- 548 57. Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-  
549 Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac.  
550 2023;33:100694. <https://doi.org/10.1016/j.lanwpc.2023.100694>.
- 551 58. Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2/3 study of S-217622 in participants with  
552 SARS-CoV-2 infection (Phase 3 part). Medicine (Baltimore). 2023;102(8):e33024.  
553 <https://doi.org/10.1097/md.00000000000033024>.
- 554 59. Wong CKH, Lau KTK, Au ICH, et al. Viral burden rebound in hospitalised patients with COVID-  
555 19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.  
556 Lancet Infect Dis. 2023;23(6):683-95. [https://doi.org/10.1016/S1473-3099\(22\)00873-8](https://doi.org/10.1016/S1473-3099(22)00873-8).
- 557 60. CDC. Interim Clinical Considerations for COVID-19 Treatment in Outpatients.  
558 [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-  
559 overview.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-overview.html). Accessed Aug 17, 2023.
- 560 61. Anderson AS, Caubel P, Rusnak JM, Investigators E-HT. Nirmatrelvir-ritonavir and viral load  
561 rebound in Covid-19. N Engl J Med. 2022;387(11):1047-9.  
562 <https://doi.org/10.1056/NEJMc2205944>.

563

564

565 **Figure legends**

566 **Fig. 1** Patient disposition flowchart



567

568

569

570

<b>Table 1</b> Demographics and baseline characteristics overall, and by disease severity at start of ensitrelvir treatment				
Baseline characteristics <sup>a</sup>	Overall ( <i>N</i> = 32)	Disease severity		
		Mild ( <i>n</i> = 21)	Moderate I ( <i>n</i> = 4)	Moderate II ( <i>n</i> = 7)
Sex				
Male	18 (56.3)	9 (42.9)	3 (75.0)	6 (85.7)
Age, yr	73.5 ± 10.9	75.9 ± 9.0	70.8 ± 9.1	67.9 ± 15.4
Age groups				
20–64	7 (21.9)	2 (9.5)	1 (25.0)	4 (57.1)
65–74	9 (28.1)	6 (28.6)	2 (50.0)	1 (14.3)
75+	16 (50.0)	13 (61.9)	1 (25.0)	2 (28.6)
Pre-treatment for SARS-CoV-2 infection (day –2 to day 0)				
Remdesivir	24 (75.0)	16 (76.2)	3 (75.0)	5 (71.4)
Casirivimab/imdevimab	1 (3.1)	1 (4.8)	0 (0.0)	0 (0.0)
Molnupiravir	1 (3.1)	0 (0.0)	1 (25.0)	0 (0.0)
Remdesivir + casirivimab/imdevimab	3 (9.4)	1 (4.8)	0 (0.0)	2 (28.6)
No prior medication	3 (9.4)	3 (14.3)	0 (0.0)	0 (0.0)
SARS-CoV-2 vaccination status				
Yes	21 (65.6)	16 (76.2)	2 (50.0)	3 (42.9)
Number of vaccination doses				
0	11 (34.4)	5 (23.8)	2 (50.0)	4 (57.1)
2	3 (9.4)	2 (9.5)	0 (0.0)	1 (14.3)
3	4 (12.5)	3 (14.3)	0 (0.0)	1 (14.3)
4	8 (25.0)	6 (28.6)	2 (50.0)	0 (0.0)
5	6 (18.8)	5 (23.8)	0 (0.0)	1 (14.3)
Pneumonia (day –2 to day 0)	8 (25.0)	0 (0.0)	2 (50.0)	6 <sup>b</sup> (85.7)
Concomitant medications (days 0–4)				
Any concomitant medication	31 (96.9)	20 (95.2)	4 (100.0)	7 (100.0)
Diabetes medication	3 (9.4)	1 (4.8)	0 (0.0)	2 (28.6)
Antihypertensives	19 (59.4)	10 (47.6)	3 (75.0)	6 (85.7)
Antineoplastic agents	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Immunosuppressants	1 (3.1)	1 (4.8)	0 (0.0)	0 (0.0)
Corticosteroids for systemic use	10 (31.2)	6 (28.6)	1 (25.0)	3 (42.9)
Precautioned medicine <sup>c</sup>	19 (59.4)	12 (57.1)	2 (50.0)	5 (71.4)
Hemodialysis	7 (21.9)	2 (9.5)	2 (50.0)	3 (42.9)



571 SD standard deviation, yr year

572 <sup>a</sup>Data are presented as n (%), or mean ± SD

573 <sup>b</sup>Including two patients with aspiration pneumonia

574 <sup>c</sup>Medicines included in the “Precautions for concomitant use” section of the prescribing instructions  
575 due to potential interactions with ensitrelvir

576

Patient	Disease severity	Sex	Age (Range)	Number of vaccinations	Prior SARS-CoV-2 treatment
1	Mild	M	80-84	5	Remdesivir <sup>c</sup>
2	Moderate I	M	65-69	4	Remdesivir <sup>c</sup>
3	Moderate II	M	70-74	5	Remdesivir
4	Mild	F	80-84	2	Remdesivir <sup>c</sup>
5	Moderate II	M	90-94	0	Remdesivir <sup>c</sup>
6	Mild	M	75-79	0	Remdesivir <sup>c</sup>
7	Mild	F	50-54	2	Remdesivir <sup>c</sup>
8	Mild	F	70-74	0	Remdesivir <sup>c</sup>
9 <sup>a</sup>	Mild	F	75-79	0	Remdesivir <sup>c</sup>
10 <sup>b</sup>	Moderate I	F	60-64	0	Molnupiravir
11	Mild	F	80-84	5	Remdesivir <sup>c</sup>
12	Mild	M	75-79	4	Remdesivir <sup>c</sup>
13	Moderate II	F	50-54	3	Remdesivir
14	Moderate II	M	80-84	2	Remdesivir <sup>c</sup>
15	Mild	M	75-79	0	
16	Mild	F	65-69	0	Remdesivir <sup>c</sup>
17	Moderate I	M	81-84	4	Remdesivir <sup>c</sup>
18	Mild	F	75-79	3	Remdesivir <sup>c</sup>
19	Mild	F	70-74	4	Remdesivir
20	Mild	M	55-59	4	
21	Mild	F	80-84	4	Remdesivir <sup>c</sup>
22	Mild	M	80-84	3	Remdesivir <sup>c</sup>
23	Moderate II	M	60-64	0	Remdesivir
24	Mild	F	80-84	4	Remdesivir <sup>c</sup> + casirivimab/imdevimab
25	Moderate II	M	55-59	0	Remdesivir + casirivimab/imdevimab
26	Mild	M	70-74	5	Remdesivir <sup>c</sup>
27	Mild	F	90-94	5	Remdesivir <sup>c</sup>
28	Mild	M	70-74	5	Casirivimab/imdevimab
29	Moderate II	M	55-59	0	Remdesivir + casirivimab/imdevimab
30	Moderate I	M	70-74	0	Remdesivir
31	Mild	M	75-79	3	Remdesivir <sup>c</sup>
32	Mild	F	70-74	4	Remdesivir <sup>c</sup>

577 ANCA anti-neutrophil cytoplasmic antibody, BSI bloodstream infection, F female, LOS length of stay,

578 M male

579 <sup>a</sup>Patient received rituximab at day –49

580 <sup>b</sup>Patient received rituximab at day –16

581 †Patient received  $\geq 3$  days of remdesivir

**Table 3** Virology outcomes

Patient	Quantitative viral antigen (pg/mL)														
	Days from start of ensitrelvir administration														
	Day -1 and Day -2	Day 0	Day 1	Day 2	Day 3	Day 4 (EOT)	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13
1	5000	5000		571.44			21.75	18.67	9.43	2.81	0.06	4.79	0.01	0.10	
2	206.25	3429.86	235.08	10.35	1.06	0.95									
3	5000		5000			113.88		0.01							
4	255.09	5000			36.55		25.72	1.61	0.30	0.01					
5	5000	5000		5000	5000	5000				1233.07	494.52		254.76	8.67	44.64
6	5000	5000		1394.43		39.12	43.49	46.30		28.65	0.83	0.89			
7		5000		1676.19					27.73						
8	5000	2728.74	3736.13	142.46		13.50	0.30								
9	5000	5000		2587.88		4.77	1210.73		5000	5000	5000				
10		1227.48		182.59	200.71										
11	5000	5000	5000		1086.83	4091.46			16.27	11.83	3.76	1.73	0.01		
12	5000			1.04	0.11										
13	5000		5000			0.75									
14	5000	5000			87.07	25.39	8.50	6.81	7.94	94.59	0.14	2.29	0.05	1.73	0.57
15		5000			5000		665.36		352.02			8.56	1.30	4.21	0.01
16	5000	5000		53.22			2.10	0.62							
17	5000	5000			537.86		84.40	7.89	43.06	3.56	2.08	0.01	0.06		
18	4328.71	5000		5000			2468.05		5000		3637.23			114.93	12.95
19	5000			344.33											
20		5000 <sup>a</sup>			5000	97.79		344.12	5000				4664.69		
21	1727.71	2393.09		1354.45			2.51	1.61	1.05	2.59	1.03	0.01			
22	5000		5000			7.42	8.09	1.97	4.39	0.71	2.78	0.67	1.72	0.08	0.24
23		88.50	2.89	0.09											
24	5000	5000			223.72		2.37	8.01	5.99	41.02		1.23	0.01		
25	5000		267.69		38.25				84.65	301			38.23	2.40	8.13
26	1305.00	5000			1021.42				19.95	1.89	0.57	0.24			
27	5000			1767.49	274.52	245.85	147.76	111.48			3.44	6.81	1.92	1.15	0.56

28		PCR Ct 16.6	5000			168.50			86.65	1.39	14.97	6.59	496.04		
29	1635.16		115.32		1463.78		41.1								
30	5000		1125.20												
31	5000	5000		5000		1330.12									
32	5000	5000		1292.38			63.29		9.86	11.31	1.56	0.01			

582 Ct cycle threshold, EOT end of treatment, PCR polymerase chain reaction

583 <sup>a</sup>PCR positive at day 0

584 Patients received ensitrelvir on days 0–4. Shading represents days the patient was hospitalized

585